Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News

  News Archive

Gyros AB, Protein Technologies Merge
Wednesday, March 16, 2016
Merger creates fast growing, global provider of sample prep, synthesis and bioanalytical tools for biotherapeutics discovery, development and manufacturing

Ultra-Sensitive Test for Cancers, HIV
Tuesday, March 15, 2016
Test developed that is thousands of times more sensitive than current diagnostics.

Paving the Way for Metastasis
Tuesday, March 15, 2016
Cancer cells remodel their environment to make it easier to reach nearby blood vessels.

Trillium Awarded $3.4 Million Funding
Monday, March 14, 2016
Trillium Therapeutics has announced that it has entered into a collaboration agreement with University Health Network and the Hospital for Sick Children to fund and undertake a research program entitled "SIRPaFc: Translating Genomics Research Into a Novel Cancer Immunotherapy."

NanoString Technologies and Cell Signaling Technology Announce Agreement
Friday, March 11, 2016
Company has announced agreement with Cell Signaling Technology to use highly validated antibodies from CST in NanoString's 3D BiologyTM Protein Profiling Panels.

Infant Milk Formula Does Not Reduce Risk of Eczema and Allergies, Says New Study
Wednesday, March 09, 2016
Researchers at Imperial College London have found a type of baby formula does not reduce allergy risk - despite previous claims to the contrary.

SomaLogic Raises Up to $60.5 Million From Visium Healthcare Partners
Tuesday, March 08, 2016
Company has announced that it has received up to $60.5 million through a combination of debt and equity financing from Visium to support strategic growth initiatives.

Cancer Cells’ Evasive Action Revealed
Friday, March 04, 2016
Rice, MD Anderson scientists analyze suppression of proteins key to immune recognition.

Chi-Med Initiates Sulfatinib Phase II Clinical Trial in Thyroid Cancer
Thursday, March 03, 2016
Company has initiated an open-label Phase II clinical trial to evaluate the efficacy and safety of sulfatinib (HMPL-012) in patients with differentiated thyroid cancer (“DTC”) or medullary thyroid cancer (“MTC”).

<< 3 4 5 6 7 8 9 >>
Showing Results 51 - 60 of 3304
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!